Document is current
Any future updates will be listed below
-
Authors
Leach, Amanda Jane https://orcid.org/0000-0002-4638-8392
Mulholland, Edward Kim
Santosham, Mathuram
Torzillo, Paul John
McIntyre, Peter
Smith-Vaughan, Heidi
Wilson, Nicole
Arrowsmith, Beth
Beissbarth, Jemima
Chatfield, Mark D.
Oguoma, Victor M.
Morris, Peter Stanley
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (605810)
Financial Markets Foundation for Children (2012-057)
- License Information
-
More Information
Article History
Received: 21 August 2020
Accepted: 10 February 2021
First Online: 8 March 2021
Ethics approval and consent to participate
: Ethical approval has been obtained from Human Research Ethics Committees of the Northern Territory Department of Health and Menzies School of Health Research (NHMRC Reg no: EC00153), the Central Australian HREC (NHMRC Reg no: EC00155) and West Australian Aboriginal Health Ethics Committee (WAAHEC- 377-12/2011). Parents or guardians provided signed informed consent for their infant’s participation.
: Not Applicable.
: Between 2010 and 2012, AJL received research funds Pfizer (manufacturers of Prevenar13™). In 2013, AJL received financial support from GSK and Pfizer to attend conferences. In 2018 AJL served on an advisory board for GSK. KM has served on an advisory board for GSK. GSK provided in-kind support for the Vietnam Pneumococcal trial, of which KM is the PI. MS served on the scientific advisory boards of Pfizer and GSK. MS also received research grants from Pfizer and GSK. PT and PMcI have no financial or other competing interests.
